EPI-743
Phase 2Small molecule
EPI-743 is one of 152 small molecule programs targeting Noise-Induced Hearing Loss. It is currently in Phase 2.
7
Indications
13
Total Trials
0
Active Trials
151
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
160 competitors in Autism Spectrum Disorder
#DrugCompanyPhaseTrials
1Vraylar
AbbViePhase 3
Elavil
AstraZenecaPhase 3
Bumex
VValidus Pharmaceuticals
Phase 3
Rexulti
OtsukaPhase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 3
Glucophage
EMD SeronoPhase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Hetlioz
VVanda Pharmaceuticals
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Karx-EC
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ataxia2 trials
Mitochondria2 trials
Autism Spectrum Disorder1 trial
6 more indications
Neuropathy1 trial
Impairment1 trial
EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment
Completed·—·Phase 2·NCT01793090·30 enrolled
Leigh syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EPI-743. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEdison Pharmaceuticals Inc